ME 23ANDME HLDG CO

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country

SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film and the film’s groundbreaking  program. Seat16 allows anyone to gift $16 or more to purchase an ORIGIN movie ticket for a young person who might not otherwise be able to purchase a ticket to the film. For 23 days, 23andMe will donate 100 seats daily to support the program.

ARRAY, the multi-platform arts and social impact collective founded by Ava DuVernay, created the Seat16 initiative to ensure that 10,000 young people across the nation get to experience ORIGIN.

Written, directed, and produced by Academy Award nominee Ava DuVernay, ORIGIN explores the mystery of history, the wonders of romance, and a fight for our future. While investigating the global phenomenon of caste and its dark influence on society, a journalist faces unfathomable personal loss and uncovers the beauty of human resilience. With an expansive cast that includes Academy Award nominee Aunjanue Ellis-Taylor, Jon Bernthal, and Niecy Nash-Betts, the film was inspired by Pulitzer Prize-winning journalist Isabel Wilkerson's novel Caste: The Origin of Our Discontents.

“It’s a scientific fact we are all 99.5 percent genetically identical. We are more alike than we are different and sometimes people forget humans have created hierarchies and caste systems. As a brand we focus on the knowledge that we are all connected, equally, through our DNA,” said Tracy Keim, Chief Brand Officer at 23andMe. “Supporting Ava DuVernay, ARRAY and the ORIGIN team by purchasing tickets for young adults through their Seat 16 program, encourages a new generation to have the opportunity to be educated through the film’s storytelling about our connection, not our differences.”

View the film's trailer . Through her foundation, 23andMe co-founder and CEO Anne Wojcicki helped fund the film along with several other non-profits.

About 23andMe

23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit .

Contacts

Media Contact: 



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 23ANDME HLDG CO

 PRESS RELEASE

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00...

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual ...

 PRESS RELEASE

23andMe announces CEO’s intention to pursue a potential take-private

23andMe announces CEO’s intention to pursue a potential take-private SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and Exchange Commission. Ms. Wo...

 PRESS RELEASE

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs...

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6 23ME-00610, antibody targeting CD200R1: Preclinical data will be presented on targeting the CD200R1 pathway in T cells and natural killer cells using 23ME-00610 as a single agent, or in combination with other anti-tumor therapies SAN DIEGO, April...

 PRESS RELEASE

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibo...

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial ev...

 PRESS RELEASE

23andMe Launches New Feature Connecting Customers to Historical Indivi...

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and migration SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for 23andMe+ Premium and Total Health members, that uncovers DNA connections to 335 unique historical individuals, from med...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch